Atezo+Bev study for pretreated patients

JRCT ID: jRCT1041200068

Registered date:25/11/2020

Basic Information

• Recruitment status: Not Recruiting
• Health condition(s) or Problem(s) studied: hepatocellular carcinoma
• Date of first enrollment: 26/11/2020
• Target sample size: 28
• Study type: Interventional
• Intervention(s): Atezolizumab and bevacizumab combination therapy

Outcome(s)

• Primary Outcome: Progression-free survival
• Secondary Outcome: Overall survival, 6-month progression-free survival rate, 1year survival rate, Time to progression, Objective response rate, Tumor control rate, Subsequent therapy, Relative dose intensity, Adverse events

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: Not applicable
• Gender: Both
• Include criteria: clinically diagnosed as hepatocellular carcinoma; unsuitable for local therapy; previously treated by systemic therapy; Preserved liver function; 20 years or older; ECOG Performance status <=2; preservation of major organ function; written informed consent
• Exclude criteria: refractory ascites or pleural effusion; risky varices; double cancer; metastases to central nervous system; severe complication; pregnant or lactating women, or women of childbearing potential; mental disorder; patients who investigator regards as inappropriate for candidate

Related Information

• Primary Sponsor: Yamashita Tatsuya